Replies to post #249027 on Biotech Values

[sks144]

Actually you are incorrect. They eliminated the second cohort due to the uptake of Trodelvy in 2L settings. There is only cohort, and it’s open to those previously treated with Keytruda to be eligible in this cohort.

[DewDiligence]

GTHX—(-52%)—reports unsuccessful interim analysis in TNBC phase-3 trial:

https://finance.yahoo.com/news/g1-therapeutics-continue-pivotal-phase-210500078.html

The trial will continue to final analysis, but the unsuccessful interim analysis makes it unlikely that the final analysis will show highly robust efficacy.